Effect of aficamten on cardiac structure and function in patients with symptomatic nonobstructive hypertrophic cardiomyopathy - Results from the ACACIA-HCM trial

29 August 2026 (16:15 - 16:30)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Doctor Sheila Hegde

University of Texas Southwestern Medical Center, Dallas (United States of America)

3 More presentations in this session

Presentation thumbnail

Aficamten vs. Metoprolol Monotherapy in Obstructive Hypertrophic Cardiomyopathy According to Pre-Trial Treatment in MAPLE-HCM

Doctor F. Dominguez (Madrid, ES)

Presentation thumbnail

Deep Learning Model for Detection, Phenotyping, and Left Ventricular Gradient Estimation in Hypertrophic Cardiomyopathy Using Echocardiography: Development and Multinational External Validation

Doctor F. Alenezi (Durham, US)

Presentation thumbnail

Safety and efficacy of treatment with mavacamten for up to 5 years in patients with obstructive hypertrophic cardiomyopathy: final results from MAVA-LTE

Doctor A. Owens (Philadelphia, US)

Access the full session

Session thumbnail

Late-Breaking Clinical Science: hypertrophic cardiomyopathy

The Event

Event poster

ESC Congress 2026

29 August 2026 16:15 CET

You may be interested in

Congress Presentation

ACACIA-HCM: Aficamten for symptomatic nonobstructive hypertrophic cardiomyopathy

28 August 2026

Congress Presentation

Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

1 September 2024

Congress Session

Hypertrophic cardiomyopathy: from gene to treatment

31 August 2025

Congress Presentation

REDWOOD-HCM-Cohort 4: Aficamten in non-obstructive HCM

20 May 2023

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources